Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome) Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome).
Found 1 Approved Drug for Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome)
Naglazyme
Generic Name
Galsulfase
Naglazyme
Generic Name
Galsulfase
Form: Solution
Method of administration: Intravenous
FDA approval date: June 09, 2005
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity. NAGLAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity. ( 1 )
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances